THOR-707: An engineered IL-2 for the treatment of solid tumors with superior pre-clinical efficacy and safety evidence

Marcos E. Milla; Jerod L. Ptacin; Carolina E. Caffaro; Hans R. Aerni; Lina Ma; Kristine M. San Jose; Michael J. Pena; Robert W. Herman; Yelena Pavlova; David B. Chen; Laura K. Shawver; Lilia K. Koriazova; Ingrid B. Joseph.
Synthorx Inc. La Jolla, CA

THOR-707: A Reprogrammed IL-2 That Expands Lymphocytes Without Inducing Eosinophil Proliferation

- At the approved clinical dose (0.037 mg/kg), abolishes IL-2-induced eosinophilia, consistently with lymphocyte proliferation and favors a beneficial vascular leak syndrome, a fetal adverse event

At Doses Leading to Maximal PD, THOR-707 Expands Lymphocytes Without Eosinophilia in NHP

- Unlike adalimumab, THOR-707 Shows Strong Bias for Expanding Tumor-Fighting Lymphocytes vs. Eosinophils Responsible for VLS; no increase in long weights up to 1 mg/kg

Repeat Dosing of THOR-707 in NHP Elevated CD8+ T Cells in the Lymphocyte Population and Achieved Ki67 Expression (88%)

Summary

- Synthorx Expanded Genetic Alphabet technology platform was applied to the discovery of THOR-707, an engineered form of IL-2 with a stable, covalent PEG incorporation at a single targeted position
- THOR-707 displays a “not-alpha” pharmacological profile: it abolishes the IL-2Rα complex at a high affinity, because of the α chain
- Improved Selectivity: Reduced CD4+ Treg bias with retained stimulatory activity of CD8+ T and NK cells in preclinical studies
- Increased Therapeutic Index: No induction of vascular leak syndrome in Cynomolgus non-human primate (NHP) up to 1 mg/kg
- Convenient dosing schedule: Expected CD8+ T-cell killing or less frequent
- Reduced Risk of Immunogenicity: Cooler attachment of stabilizing PEG; conjugation site devoid of MHC stimulatory activity of CD8+ T and NK cells in preclinical studies

Background

IL-2 Dual Pharmacology Prevents Aidesikun from Dosing for Maximal CD8+ T Cell Expansion

- IL-2 binds to two different receptor forms
  - At high affinity, it engages the IL-2 receptor (IL-2Rα) complex expressed on CD4+ T cells as the dominant cell type in in vitro stimulation assays
  - At lower affinity, it engages the IL-2Rαγc complex expressed on CD8+ T and natural killer (NK) cells. These cells are critical for anti-tumor response

Design Strategy for Not-alpha THOR-707 IL-2

Single, stable PEG covalently attached to a novel amino acid site to make a “not-alpha” IL-2 protein

Screening: SAR for THOR-707 “Not-alpha” IL-2 Synthor

- IL-2Rαγc crystallographic interface examined to identify potential sites for biocomplementation
- Pegylated variants tested via Uscs/PathHunter™ assay (IL-2Rγc α or γc recombinant CHO cells)

- Identified three sites with not-a-IL-2Rγc profile. THOR-707 selected based on expression yield

Human IL-2 Pharmacology is Comparable Between Human and NHP, but not Between Human and Mouse IL-2R

- Reduced CD4+ Treg bias with retained
- Cell-based studies (pSTAT5) show that human IL-2 potency depends on the cell type
- Comparable potency across species for Treg cells expressing IL-2Rγc content comparable
- Dynamic drop in potency in mouse CD8+ T cells relative to human (74%) and NHP (65%)

CD8+ T cells are the target cell for the anti-tumor pharmacological effect of IL-2. Therefore, THOR-707 is dosed in mice at relatively high levels, to compensate for a 2.1x decreased potency at the mouse IL-2 receptor (74%) chain

No eosinophilia or vascular leak syndrome was observed at any dose level. This confirms that THOR-707 can be dosed at levels eliciting full pharmacodynamic responses without VLS, a severe adverse event previously associated with abalosulin

Binding Affinity of THOR-707 to Human IL-2 Receptor α and β Chains

- THOR-707 does not engage IL-2Rα chain yet binds the β chain similarly to IL-2.
- As expected for a not-alpha IL-2, THOR-707 activates with similar potency the IL-2Rα and β complexes in human primary T cells

THOR-707 Activation of Human CD4+ Treg and CD8+ Teff Cells Ex vivo (gSTAT5)

- Stable pulation confers to THOR-707 high plasma AUC in both NHP and mouse
- Full PD effect on peripheral CD8+ T cell IL-2Rα γc topical activation marker pSTAT5, and early proliferation marker Ki67

THOR-707 Pharmacokinetics and In Vivo Activation of Mouse and Non-human Primate (NHP) CD8+ T Cells

- THOR-707 Shows Increased Distribution and Retention in C57B16 Tumors

- THOR-707 drives CD8+ tumor infiltration comparable to levels observed with a combination of CTLA-4 and PD-1 checkpoint inhibitor mAb8s in this syngeneic melanoma tumor model
- In contrast, THOR-707 does not change over time Treg infiltration

Peripheral CD8+ T Cell Activation and Proliferation

- THOR-707 shows Additive Efficacy with an Anti-PD-1 mAb in C57B16 Tumor-bearing Mice Day 14 Tumor Size Measurements

- THOR-707 shows Dose-dependent Single Agent Efficacy in CT-26 Tumor-bearing Mice Day 17 Tumor Size Measurements

7TGA tumor half life was ~1X plasma half life (24.6 vs 12.6 h). Synthorx penetrates the tumor compartment and is retained there

- Based on AUC, 8% of plasma levels are in the tumor (plotted 3.6×): increased tumor distribution

- THOR-707 induces durable CD8+ T-cell infiltration in mouse B16F10 Tumors

- THOR-707 shows single agent or combination efficacy in multiple models

- THOR-707 exhibits extended life-and-high-AUC in both mouse and pig: resulting in IL-2Rα occupancy levels that drive maximal activation and proliferation of CD8+ effector and memory cells, and T-cell cells, with little or no expansion of CD4+ regulatory T cells

- THOR-707 inhibits extended life-and-high-AUC in both mouse and pig: resulting in IL-2Rα occupancy levels that drive maximal activation and proliferation of CD8+ effector and memory cells, and T-cell cells, with little or no expansion of CD4+ regulatory T cells

- THOR-707 shows durable infiltration of CD8+ T cells into CT-26 syngeneic mouse tumors. In the model, it displays dose-dependent single-cell efficacy in these tumors, and additivity in combination with a PD-1 checkpoint inhibitor

- No eosinophilia or vascular leak syndrome was observed at any dose level. This confirms that THOR-707 can be dosed at levels eliciting full pharmacodynamic responses without VLS, a severe adverse event previously associated with abalosulin

- Reduced Risk of Immunogenicity
- No eosinophilia or vascular leak syndrome was observed at any dose level. This confirms that THOR-707 can be dosed at levels eliciting full pharmacodynamic responses without VLS, a severe adverse event previously associated with abalosulin

- Reduced Risk of Immunogenicity
- No eosinophilia or vascular leak syndrome was observed at any dose level. This confirms that THOR-707 can be dosed at levels eliciting full pharmacodynamic responses without VLS, a severe adverse event previously associated with abalosulin

- Reduced Risk of Immunogenicity
- No eosinophilia or vascular leak syndrome was observed at any dose level. This confirms that THOR-707 can be dosed at levels eliciting full pharmacodynamic responses without VLS, a severe adverse event previously associated with abalosulin

- Reduced Risk of Immunogenicity
- No eosinophilia or vascular leak syndrome was observed at any dose level. This confirms that THOR-707 can be dosed at levels eliciting full pharmacodynamic responses without VLS, a severe adverse event previously associated with abalosulin